Claims for Patent: 10,793,615

Summary for Patent: 10,793,615

Title:	Long-acting co-agonists of the glucagon and GLP-1 receptors
Abstract:	Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
Inventor(s):	Palani; Anandan (Bridgewater, NJ), Nargund; Ravi (East Brunswick, NJ), Carrington; Paul E. (South San Francisco, CA), Sawyer; Tomi (Southborough, MA), Deng; Qiaolin (Edison, NJ), Pessi; Antonello (D\'Europa, IT), Bianchi; Elisabetta (Pomezia, IT), Orvieto; Federica (Pomezia, IT)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	15/759,911
Patent Claims:	1. A peptide comprising the formula TABLE-US-00023 (SEQ ID NO: 50) HX.sup.2QGTFTSX.sup.9X.sup.10SX.sup.12YX.sup.14DX.sup.16RAAX.sup.20X.sup.2- 1X.sup.22VX.sup.24WLX.sup.27X.sup.28TX.sup.30-NH.sub.2 wherein X.sup.2 is aminoisobutyric acid (aib), D-Ser or alpha-Methyl-L-Serine (alpha-MS); X.sup.9 is Asp or alpha-Methyl-L-Aspartic acid (alpha-MD); X.sup.10 is Lys conjugated to a fatty diacid, p-aminomethyl-L-phenylalanine (pAF) conjugated to a fatty diacid or Tyr-; X.sup.12 is Lys conjugated to a fatty diacid, pAF conjugated to a fatty diacid, Lys, or (1S,2S)-Fmoc-2-aminocyclopentane carboxylic acid (.beta.c); X.sup.14 is Leu or alpha-L-Leucine (alpha-ML); X.sup.16 is aib, Ala, or Glu; X.sup.20 is Lys is conjugated to a fatty diacid, pAF conjugated to a fatty diacid or Gln; X.sup.21 is Lys conjugated to a fatty diacid, pAF conjugated to a fatty diacid, Asp, or alpha-MD; X.sup.22 is Phe or alpha-Methyl-L-phenylalanine (alpha-MF); X.sup.24 is Gln (1S,2S)-Fmoc-2-aminocyclopentane carboxylic acid (.beta.c), Lys conjugated to a fatty diacid or pAF conjugated to a fatty diacid; X.sup.27 is L-Met sulphone or Leucine; X.sup.28 is Asp, alpha-MD, alpha-Methyl-L-Tryptophan (alpha-MW), Lys, Ala, Lys conjugated to a fatty diacid, or pAF conjugated to a fatty diacid; and X.sup.30 is Lys linked at the C-terminus to gamma-Glu when X.sup.27 is Leu and X.sup.28 is Ala, or absent; with the proviso that for each peptide, only one of X.sup.10, x.sup.12, x.sup.20, X.sup.21, X.sup.24, or X.sup.28 is conjugated to a fatty diacid. 2. The peptide of claim 1, wherein the fatty diacid comprises a C14, C15, C16, C17, C18, C19, or C20 fatty diacid. 3. The peptide of claim 1, wherein the peptide comprises the fatty diacid conjugated to the Lys or pAF via a gamma-Glu, gamma-Glu linker. 4. The peptide of claim 1, wherein the peptide comprises the fatty diacid conjugated to Lys or pAF via a PEG.sub.2PEG.sub.2-gamma-Glu linker wherein PEG.sub.2 is 8-amino-3,6-dioxaoctanoic acid. 5. The peptide of claim 1, wherein the peptide comprises at X.sup.10 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid. 6. The peptide of claim 1, wherein the peptide comprises at x.sup.12 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid. 7. The peptide of claim 1, wherein the peptide comprises at x.sup.20 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid. 8. The peptide of claim 1, wherein the peptide comprises at x.sup.21 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid. 9. The peptide of claim 1, wherein the peptide comprises at x.sup.24 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid. 10. A composition comprising one or more peptides of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 11. A composition comprising one or more peptides of claim 1, or pharmaceutically acceptable salt thereof, an insulin or insulin analog, and a pharmaceutically acceptable carrier. 12. The composition of claim 11, wherein the insulin analog comprises insulin detemir, insulin glargine, insulin glulisine, insulin degludec, or insulin lispro. 13. A method for treating a patient for a metabolic disease or disorder comprising administering to a patient in need thereof an effective amount of one or more of the peptides of claim 1 to treat the metabolic disease or disorder in the patient wherein, the metabolic disease or disorder comprises diabetes, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity. 14. The method of claim 13, wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes. 15. A method for treating a metabolic disease or disorder in a patient comprising administering to the patient in need thereof an effective amount of one or more of the peptides of claim 1 and administering to the patient in need thereof an effective amount of a composition comprising an insulin or insulin analog to treat the metabolic disease or disorder in the patient, wherein the metabolic disease or disorder comprises diabetes, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity. 16. The method of claim 15, wherein the insulin analog comprises insulin detemir, insulin glargine, insulin levemir, insulin glulisine, insulin degludec, or insulin lispro. 17. The method of claim 15, wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes.

Details for Patent 10,793,615

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 14, 1996		2036-10-21
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	August 06, 1998		2036-10-21
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	September 06, 2007		2036-10-21
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	June 06, 2017		2036-10-21
Eli Lilly And Company	HUMALOG	insulin lispro	Injection	020563	November 15, 2019		2036-10-21
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	April 20, 2000		2036-10-21